These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30941698)

  • 21. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
    Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
    Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. "Don't Think Twice, It's All Right": Using Additional Data to Reduce Uncertainty Regarding Oncologic Drugs Provided Through Managed Access Agreements in England.
    Kang J; Cairns J
    Pharmacoecon Open; 2023 Jan; 7(1):77-91. PubMed ID: 36123583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
    Lakdawalla DN; Chou JW; Linthicum MT; MacEwan JP; Zhang J; Goldman DP
    JAMA Oncol; 2015 May; 1(2):196-202. PubMed ID: 26181023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
    Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
    Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Access to expensive drugs in the NHS: myths and realities for cancer patients.
    Mehta AB; Low E
    Int J Clin Pract; 2007 Dec; 61(12):2126-9. PubMed ID: 17997811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Claxton L; O'Connor J; Woolacott N; Wright K; Hodgson R
    Pharmacoeconomics; 2019 May; 37(5):645-654. PubMed ID: 30298279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. UK newspaper reporting of the NHS cancer drugs fund, 2010 to 2015: a retrospective media analysis.
    Lewison G; Aggarwal A; Roe P; Møller H; Chamberlain C; Sullivan R
    J R Soc Med; 2018 Oct; 111(10):366-373. PubMed ID: 30212638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.
    Walker S; Palmer S; Erhorn S; Brent S; Dyker A; Ferrie L; Horsley W; Macfarlane K; White S; Thomas S
    Health Technol Assess; 2009 Jun; 13 Suppl 1():35-40. PubMed ID: 19567212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies.
    da Veiga CRP; da Veiga CP; Drummond-Lage AP
    Crit Rev Oncol Hematol; 2018 Sep; 129():133-145. PubMed ID: 30097232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK.
    Hoyle M; Crathorne L; Garside R; Hyde C
    Health Technol Assess; 2011 May; 15 Suppl 1():61-7. PubMed ID: 21609654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.
    MacLeod TE; Harris AH; Mahal A
    Patient; 2016 Jun; 9(3):201-22. PubMed ID: 26370257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Grimm SE; Armstrong N; Ramaekers BLT; Pouwels X; Lang S; Petersohn S; Riemsma R; Worthy G; Stirk L; Ross J; Kleijnen J; Joore MA
    Pharmacoeconomics; 2019 May; 37(5):655-667. PubMed ID: 30293207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.
    Fleeman N; Bagust A; Beale S; Boland A; Dickson R; Dwan K; Richardson M; Dundar Y; Davis H; Banks L
    Pharmacoeconomics; 2015 Sep; 33(9):893-904. PubMed ID: 25906420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes.
    Varnava A; Bracchi R; Samuels K; Hughes DA; Routledge PA
    Pharmacoeconomics; 2018 May; 36(5):613-624. PubMed ID: 29520603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
    Niraula S; Nugent Z
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
    [No Abstract]   [Full Text] [Related]  

  • 40. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.